Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
6%(1 trials)

Phase Distribution

Ph phase_3
1
6%
Ph phase_1
4
24%
Ph phase_2
12
71%

Phase Distribution

4

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
4(23.5%)
Phase 2Efficacy & side effects
12(70.6%)
Phase 3Large-scale testing
1(5.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

94.1%

16 of 17 finished

Non-Completion Rate

5.9%

1 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(16)
Terminated(1)

Detailed Status

Completed16
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (23.5%)
Phase 212 (70.6%)
Phase 31 (5.9%)

Trials by Status

completed1694%
withdrawn16%

Recent Activity

0 active trials
Showing 5 of 17
completedphase_2

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

NCT03643107
completedphase_1

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

NCT00374660
completedphase_2

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00053365
completedphase_2

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

NCT00124566
withdrawnphase_2

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00003786
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT03643107Phase 2

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Completed
NCT00374660Phase 1

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Completed
NCT00053365Phase 2

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Completed
NCT00124566Phase 2

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Completed
NCT00003786Phase 2

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Withdrawn
NCT00012038Phase 1

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

Completed
NCT00003390Phase 2

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

Completed
NCT00019552Phase 2

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed
NCT00005070Phase 2

Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer

Completed
NCT00005968Phase 2

Irofulven in Treating Patients With Stage IV Melanoma

Completed
NCT00005031Phase 2

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

Completed
NCT00062257Phase 2

Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

Completed
NCT00003796Phase 2

Irofulven in Treating Patients With Metastatic Breast Cancer

Completed
NCT00003997Phase 1

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Completed
NCT00003370Phase 1

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Completed
NCT00033735Phase 3

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

Completed
NCT00003760Phase 2

Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17